Tweet
Profile:
Achillion Pharmaceuticals, Inc.
300 George Street
New Haven, CT 06511
United States - Map
Phone: 203-624-7000
Fax: 203-624-7003
Website: http://www.achillion.com
Details:
Index Membership: N/A
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 42
Business Summary:
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic HCV include ACH-1625, a protease inhibitor, which is in phase IIa clinical trial for the treatment of chronic HCV; ACH-2684, a pangenotypic protease inhibitor, which is in phase I clinical trial for the treatment of chronic HCV infection; and NS5A inhibitors for the treatment of chronic HCV infection, including ACH-2928, which is to enter a phase I clinical trial, as well as various additional NS5A inhibitors in preclinical development. Its pipeline of product candidates also includes ACH-702 and ACH-2881 for drug resistant bacterial infections; elvucitabine for HIV infection; and ACH-1095 for HCV infection. The company was founded in 1998 and is based in New Haven, Connecticut.
Achillion Pharmaceuticals, Inc.
300 George Street
New Haven, CT 06511
United States - Map
Phone: 203-624-7000
Fax: 203-624-7003
Website: http://www.achillion.com
Details:
Index Membership: N/A
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 42
Business Summary:
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic HCV include ACH-1625, a protease inhibitor, which is in phase IIa clinical trial for the treatment of chronic HCV; ACH-2684, a pangenotypic protease inhibitor, which is in phase I clinical trial for the treatment of chronic HCV infection; and NS5A inhibitors for the treatment of chronic HCV infection, including ACH-2928, which is to enter a phase I clinical trial, as well as various additional NS5A inhibitors in preclinical development. Its pipeline of product candidates also includes ACH-702 and ACH-2881 for drug resistant bacterial infections; elvucitabine for HIV infection; and ACH-1095 for HCV infection. The company was founded in 1998 and is based in New Haven, Connecticut.